On September 27, 2016 Rasna Therapeutics, Inc. (OTCQB:RASP) (the "Company") (formerly Active With Me, Inc.), a development stage biotechnology company focused on the development of cancer drugs, reported it has implemented a 3.25-for-1 forward split of its common stock in effect for trading on a split-adjusted basis on Tuesday, September 20, 2016 as well as a name change and trading symbol change from Active With Me, Inc. and "ATVM" to Rasna Therapeutics, Inc. and "RASP", effective as of September 27, 2016 (Press release, Rasna Therapeutics, SEP 27, 2016, View Source [SID:SID1234515438]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a result of the stock split, every one share of issued and outstanding common stock of the Company will be converted into 3.25 shares of common stock. Proportional adjustments will be made to the Company’s options and warrants. Any fractional shares resulting from the forward stock split will be rounded up to the next whole share.